Back

dr. R.S. (Rachel) van Leeuwaarde

Research Staff Other
  • Department of Endrocine Oncology

Research Programs

Strategic Program Cancer

Research Output (26)

Diagnostic and management strategies for pNETs in Von Hippel-Lindau:a systematic review

Ahmad Saya, Naber Myrthe R, Giles Rachel H, Valk Gerlof D, van Leeuwaarde Rachel S 1 jan 2021, In: Endocrine-Related Cancer. 28 , p. 151-160 10 p.

Health-related quality of life in patients with Multiple Endocrine Neoplasia type 1

van Leeuwaarde Rachel S, Pieterman Carolina R C, May Anne M, Dekkers Olaf M, van der Horst-Schrivers Anouk N A, Hermus Ad R, de Herder Wouter, Drent Madeleine L, Bisschop Peter H, Havekes Bas, Vriens Menno R, Valk Gerlof D 4 mei 2020, In: Neuroendocrinology. 111 , p. 288-296 9 p.

177Lu-DOTATATE Plus 166Ho-Radioembolization in Patients with Neuroendocrine Tumours; A Single Center, Prospective, Interventional, Non-Comparative, Open Label, Phase II Study (HEPAR PLuS Study)

Braat A., Rutger B., Van Rooij R., Braat M., Wessels F., van Leeuwaarde R., van Treijen M., de Herder W. W., Hofland J., Tesselaar M., de Jong H., Lam M. mrt 2020, In: Neuroendocrinology. 110 , p. 249-249

Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is >= 10%?

Merola E., Gordoa Alonso T., Zhang P., Al-Toubah T., Pelle E., Liu M., Laskaratos F., de Mestier L., Lamarca A., Hernando J., Cives M., van Leeuwaarde R. mrt 2020, In: Neuroendocrinology. 110 , p. 197-197

Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS):a single-centre, single-arm, open-label, phase 2 study

Braat Arthur J A T, Bruijnen Rutger C G, van Rooij Rob, Braat Manon N G J A, Wessels Frank J, van Leeuwaarde Rachel S, van Treijen Mark J C, de Herder Wouter W, Hofland Johannes, Tesselaar Margot E T, de Jong Hugo W A M, Lam Marnix G E H 26 feb 2020, In: LANCET ONCOLOGY. 21 , p. 561-570 10 p.

Somatostatin Analogs for Pancreatic Neuroendocrine Tumors:Any Benefit When KI-67 is ≥10%?

Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pelle E, Kolasińska-Ćwikła A, Zandee W T, Laskaratos F M, de Mestier L, Lamarca A, Hernando J, Cwikla J B, Strosberg J, de Herder W W, Caplin M, Cives M, van Leeuwaarde R S 2020, In: Oncologist.

Clinical Relevance of Genetic Analysis in Patients With Pituitary Adenomas:A Systematic Review

van den Broek Medard F M, van Nesselrooij Bernadette P M, Verrijn Stuart Annemarie A, van Leeuwaarde Rachel S, Valk Gerlof D 10 dec 2019, In: Frontiers in Endocrinology. 10 16 p.

Biochemically Silent Sympathetic Paraganglioma, Pheochromocytoma, or Metastatic Disease in SDHD Mutation Carriers

Dreijerink Koen M.A., Rijken Johannes A., Compaijen C. J., Timmers Henri J.L.M., van der Horst-Schrivers Anouk N.A., van Leeuwaarde Rachel S., van Dam P. Sytze, Leemans C. René, van Dam Eveline W.C.M., Dickhoff Chris, Dommering Charlotte J., de Graaf Pim, Zwezerijnen G. J.C., van der Valk Paul, Menke-Van der Houven van Oordt C. Willemien, Hensen Erik F., Corssmit Eleonora P.M., Eekhoff E. Marelise W. 1 nov 2019, In: The Journal of clinical endocrinology and metabolism. 104 , p. 5421-5426 6 p.

The incidence of consecutive manifestations in Von Hippel-Lindau disease

van der Horst-Schrivers Anouk N A, Sluiter Wim J, Kruizinga Roeliene C, van Leeuwaarde Rachel S, Giles Rachel, Olderode-Berends Maran J W, Links Thera P 13 mei 2019, In: Familial Cancer. 18 , p. 369-376 8 p.

First Experience with 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands

van Kalmthout Ludwike, Braat Arthur, Lam Marnix, van Leeuwaarde Rachel, Krijger Gerard, Ververs Tessa, Mehra Niven, Bins Adriaan, Hunting Jarmo, de Keizer Bart 12 apr 2019, In: Clinical Nuclear Medicine. 44 , p. 446-451 6 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.